Clinical Imaging
Volume 33, Issue 6 , Pages 462-467 , November 2009

18F-Fluorodeoxyglucose uptake in uterine leiomyomas in healthy women

  • Hitomi Tsukada

      Affiliations

    • Department of Obstetrics and Gynecology, Tokai University Oiso Hospital, Kanagawa, 259-0198 Japan
    • ,
  • Masaru Murakami

      Affiliations

    • Department of Obstetrics and Gynecology, Tokai University Oiso Hospital, Kanagawa, 259-0198 Japan
    • Corresponding Author InformationCorresponding author. Department of Obstetrics and Gynecology, Tokai University Oiso Hospital, Oiso Town Kanagawa, 259-0198 Japan. Tel.: +81 463 72 3211; fax: +81 463 72 2256.
    • ,
  • Masako Shida

      Affiliations

    • Department of Obstetrics and Gynecology, Tokai University Oiso Hospital, Kanagawa, 259-0198 Japan
    • ,
  • Kimitaka Kikuchi

      Affiliations

    • Department of Obstetrics and Gynecology, Tokai University Oiso Hospital, Kanagawa, 259-0198 Japan
    • ,
  • Mio Watanabe

      Affiliations

    • Department of Obstetrics and Gynecology, Tokai University Oiso Hospital, Kanagawa, 259-0198 Japan
    • ,
  • Seiei Yasuda

      Affiliations

    • Department of Surgery, Tokai University School of Medicine, Isehara City, Kanagawa, 259-1193 Japan
    • ,
  • Yutaka Suzuki

      Affiliations

    • HIMEDIC Imaging Center, Lake Yamanaka, Yamanashi, 401-0502 Japan

Received 20 December 2008 ,Accepted 10 February 2009.

References 

  1. Lefebvre G, Vilos G, Allaire C, et al. The management of uterine leiomyomas. J Obstet Gynecol Can. 2003;25:396–405
  2. Harlow BL, Weiss NS, Lofton S. The epidemiology of sarcomas of the uterus. J Natl Cancer Inst. 1986;76:399
  3. Leibsohn S, d'Ablang G, Mishell DR, Schalerth JB. Leiomyosarcoma in a series of hysterectomies performed for presumed uterine leiomyomas. Am J Obstet Gynecol. 1990;162:968–976
  4. Schelbert HR, Hoh CK, Roral HD, et al. Procedure guideline for tumor imaging using fluorine-18-FDG. J Nucl Med. 1998;39:1302–1305
  5. Fletcher JW, Djulbegovic B, Soarces HP, et al. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008;49:480–508
  6. Yasuda S, Ide M, Fujii H, et al. Application of positron emission tomography imaging to cancer screening. Brit J Cancer. 2000;83:1607–1611
  7. Kim EK. Whole-body positron emission tomography and positron emission tomography/computed tomography in gynecologic oncology. Int J Gynecol Cancer. 2004;14:12–14
  8. Nakamoto Y, Saga T, Fujii S. Positron emission tomography application for gynecologic tumors. Int J Gynecologic Cancer. 2005;15:701–709
  9. Pandi-Taskar N. Oncologic imaging in gynecologic malignancies. J Nucl Med. 2005;46:1842–1850
  10. Wahl RL. Why nearly all PET of abdominal and pelvic cancer will be performed as PET/CT. J Nucl Med. 2004;45:82s–95s
  11. Murakami M, Miyamoto T, Iida T, et al. Whole-body positron emission tomography and tumor maker CA125 for detection of recurrence in epithelial ovarian cancer. Int J Gynecol Cancer. 2006;16(Suppl 1):99–107
  12. Umesaki N, Tanaka T, Miyama M, et al. Positron emission tomography with 18F-fluorodeoxyglucose of uterine sarcoma: a comparison with magnetic resonance imaging and power. Doppler imaging. 2001;80:372–377
  13. Umesaki N, Tanaka T, Miyama M, et al. Positron emission tomography using 2-18F-fluoro-2-deoxy-glucose in the diagnosis of uterine leiomyosarcoma. Clin Imaging. 2001;25:203–205
  14. Murakami M, Tsukada H, Shida M, et al. Whole-body positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET) for detection of recurrence in uterine sarcomas. Int J Gynecol Cancer. 2006;16:854–860
  15. Lee WL, Liu RS, Yuan CC, et al. Relationship between gonadotropin-releasing hormone agonist and myoma cellular activity: preliminary findings on positron emission tomography. Fertil Steril. 2001;75:638–639
  16. Lerman H, Metser U, Grisaru D, et al. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. J Nucl Med. 2004;45:266–271
  17. Nishizawa S, Inobushi M, Okaba H. Physiologic 18F-FDG uptake in the ovaries and uterus of healthy female volunteers. Eur J Nucl Med Mol Imaging. 2005;32:549–556
  18. Kao CH. FDG uptake in a huge uterine myoma. Clin Nucl Med. 2003;28:249
  19. Ak I, Ozalp S, Yalcin OT, et al. Uptake of 2-[18F]fluoro-2-deoxy-d-glucose in uterine leiomyoma: imaging of four patients by coincidence positron emission tomography. Nucl Med Commun. 2004;25:941–945
  20. Higashi H, Saga T, Nakamoto Y, et al. Relation between retention index in dual-phase 18F-FDG PET, and hexokinase-II and glucose transporter 1 expression in pancreatic cancer. J Nucl Med. 2002;43:173–180
  21. Kurokawa T, Yoshida Y, Kawahara K, et al. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. Int J Cancer. 2004;109:926–932
  22. Shida M, Murakami M, Tsukada H, et al. F-18 Fluorodeoxyglucose uptake in leiomyomatous uterus. Int J Gynecol Cancer. 2007;17:285–290
  23. Grisaru D, Almog B, Levine C, et al. The diagnostic accuracy of 18F-fluorodeoxyglucose PET/CT in patients with gynecological malignancies. Gynecol Oncol. 2004;94:680–684

PII: S0899-7071(09)00086-2

doi: 10.1016/j.clinimag.2009.02.005

Clinical Imaging
Volume 33, Issue 6 , Pages 462-467 , November 2009

Article Tools

* Image Usage & Resolution